Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

About this trial

The purpose of this trial is to determine if the drug nivolumab versus placebo prevents cancer recurrence in participants with bladder or upper urinary tract cancer, following surgery to remove the cancer.

This is a randomised phase 3 trial.

Patient Profile

Patients who have had invasive urothelial cancer and have a high risk of recurrence originating in the bladder, ureter, or renal pelvis, have had radical surgical resection (e.g. radical cystectomy), performed within the last 90 days and are disease free status as determined by imaging within 4 weeks of dosing.

Where’s this trial being run?

Cork University Hospital and Tallaght University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: CA209-274
Number: 16-70
Full Title:

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)

Principal Investigator: Prof Ray McDermott (Tallaght Hospital)
Type: Industry Sponsored


Recruitment Started: Global: March 2016
Ireland: October 2016
Global Recruitment Target: 640
Ireland Recruitment Target: 8